Orano Med Is A Clinical Stage Biotechnology Company Focused On Developing Targeted Therapies For Cancer Using Lead 212A Rare Alpha Emitting Radioisotopeestablished In 2009The Company Is A Subsidiary Of The Orano Group And Aims To Create Innovative Treatments For Patients Who Do Not Respond To Existing Therapiesits Primary Approach Is Targeted Alpha Therapytat Leveraging The Potent Properties Of Lead 212 To Develop New Cancer Treatment Options The Company Operates An Industrial Production Platform For Lead 212Ensuring A Consistent Supply For Its Therapiesorano Med Also Has Preclinical Laboratories In France And The United Stateswhich Play A Vital Role In Advancing Its Alpha Therapiescurrentlythe Company Is Conducting Clinical Trials To Move Its Therapies Toward Fda Approvalreflecting Its Commitment To Addressing Unmet Medical Needs In Oncology
No conferences found for this company.
| Company Name | Orano Med Llc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
